During the forecast period from 2012-2022, the growth of the UC market
will be driven largely by the entry of Johnson & Johnson's (J&J's)
Simponi and Takeda's Entyvio, which will lead to an increase in the
overall number of patients being treated with biologics in the US, EU,
Japan, and Canada. Another key event affecting the UC market is the
anticipated launch of biosimilars, given that the patent expiry of the
UC blockbusters, Remicade and Humira are set to expire in the US in 2018
and 2016, respectively.

Asacol made a significant impact in the UC market, mostly thanks to
mesalamine's well-known safety profile. In turn, Asacol is considered
the gold standard for mesalamine products in all forms (tablets,
suppositories, enemas). The active ingredient in Asacol, mesalamine,
exerts its function through its anti-inflammatory and immunosuppressive
actions as a COX inhibitor, a blocker of T-cell-activating cytokines, an
adenosine inducer, and an antibody synthesis inhibitor.

Scope

Overview of Ulcerative Colitis, including epidemiology, etiology,
symptoms, diagnosis, pathology and treatment guidelines as well as an
overview on the competitive landscape.

Detailed information on Asacol including product description, safety
and efficacy profiles as well as a SWOT analysis.

Sales forecast for Asacol for the top ten countries from 2012 to 2022

Reasons to buy

Understand and capitalize by identifying products that are most likely
to ensure a robust return

Stay ahead of the competition by understanding the changing
competitive landscape for Ulcerative Colitis

Effectively plan your M&A and partnership strategies by identifying
drugs with the most promising sales potential

Make more informed business decisions from insightful and in-depth
analysis of Asacol performance

Obtain sales forecast for Asacol from 2012-2022 in the top ten
countries